Home » Abbott, Fujirebio to Develop Ovarian Cancer Test
Abbott, Fujirebio to Develop Ovarian Cancer Test
Abbott and Fujirebio Diagnostics have signed a licensing agreement to develop an ovarian cancer test for use with Abbott’s automated Architect diagnostic analyzers. Fujirebio will develop and manufacture the HE4 biomarker. The HE4 test, which is expected to be available this year, will provide a tool to help define a pelvic mass so appropriate treatment can be identified earlier and more effectively, Fujirebio says in a statement.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May